IL-SEVAN
23.6.2022 14:02:12 CEST | Business Wire | Press release
Sevan Multi-Site Solutions, Inc. (Sevan ) has earned the exclusive designation as a Certified Veteran’s Business Enterprise™ (VBE) from the National Veteran-Owned Business Association (NaVOBA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220622005984/en/
Sevan, a global leader in innovative program management for clients with multiple sites, partnered with NaVOBA to receive the certification—which creates corporate contracting opportunities for veteran and service-disabled veteran businesses through certification, advocacy, outreach, recognition and education.
“Sevan is honored to be a Certified Veteran’s Business Enterprise™ via the National Veteran-Owned Business Association,” said Jim Evans, Founder and CEO of Sevan. “As a West Point graduate and former special forces officer, it’s a privilege to receive this designation. We greatly look forward to additional partnerships with other veteran owned organizations and clients across the restaurant, retail and government spaces.”
To be eligible for certification, organizations must be at least 51% owned, operated and controlled by one or more U.S. military veterans.
“Sevan becoming a Certified Veteran’s Business Enterprise™ is an incredibly exciting milestone for our team and organization,” said David Hendrix, Chief Commercial Officer. “Many of our clients are looking to maximize their diverse spend goals. Sevan now qualifies as a diverse supplier. We look forward to partnering with our current and new clients with this stamp of approval to contribute to our nation’s overall diverse spend initiatives.”
The certification process included a comprehensive list of business requirements and criteria, along with a rigorous examination and verification process. Certification enables Sevan to be more unique and competitive in the multi-site space.
“Corporations will not risk the accuracy of their Supplier Diversity spending goals by recording spend on contracts with firms that say they are owned by veterans if they aren’t absolutely certain of the ownership, operation and control of that firm,” said NaVOBA President Matthew Pavelek. “Working with a third-party nonprofit organization like NaVOBA and its VBE certification program provides that certainty.”
In 2022, Sevan was recognized as an Employee-Rated Great Place to Work® for the 9th consecutive year. In 2021, Sevan ranked on the Inc. 5000 list of the nation’s fastest-growing private companies for the 4th consecutive year. Also in 2021, Sevan ranked No. 21 on Engineering News-Record (ENR)’s Top 50 Program Management Firms, No. 44 on ENR’s Top 100 Construction Management-for-Fee Firms and earned the Gold HIRE Vets Medallion Award. In 2020, Sevan ranked No. 124 on the Financial Times FT 1000 list of America’s Fastest-Growing Companies. Visit our website to learn more about Sevan.
About Sevan
Sevan is an innovative global leader in design, program management, construction services and data analytics for organizations with multiple sites. Sevan puts capital to work—creating speed and scale—via dramatically enhanced efficiencies and accelerated schedules for high-quality program rollouts to maximize ROI. We partner with some of the world’s biggest brands and serve the unique needs of clients in the restaurant, retail and government spaces and create unlimited value. Sevan’s team spans across four countries and 40 states. As an extension of your team, our in-house experts manage capital improvement initiatives through every step of a program’s lifecycle.
Sevan helps iconic brands optimize their multi-site construction and facility programs in the United States and internationally. Sevan is headquartered near Chicago in Downers Grove, Illinois and has an international office in London.
Sevan has a passion for sustaining people, the environment and its clients’ businesses. Sevan strategically guides worldwide brands—including 7-Eleven, AAFES, Albertsons, Amtrak, BP, Carbon Health, Chipotle, Corvias, DaVita, Department of Veteran Affairs, Focus Brands, HCA Healthcare, HEB, Inspire Brands, Jiffy Lube, Kroger, Luxottica, McDonald’s, Motor Fuel Group, Office Depot, Popeyes, QDOBA, Starbucks, Sunoco, Walgreens Boots Alliance, Walmart, WOW Carwash and Yum! Brands—through their entire turnkey program lifecycle. Sevan rolls out multi-site initiatives efficiently, predictably and transparently. Applying breakthrough technology solutions, Sevan optimizes construction of new builds, rebuilds, remodels and renovations. Sevan has licensed architects in 49 states as well as D.C., Canadian provinces, Guam and the Northern Mariana Islands. Sevan has professional engineers on staff and general contractor licenses in more than 25 states. Since Sevan’s inception in 2011, the team has refreshed more than 25,000 retail stores, 17,000 restaurants and 32,000 healthcare sites. The team has also completed more than 32,000 surveys, totaling more than 1 billion square feet. Sevan Elevate, a program that reinforces and continuously improves safety and sustainability across the company, is designed to impactfully deliver excellence to Sevan’s people and clients.
To learn more about Sevan’s offerings, visit www.sevansolutions.com .
For more information, please contact Hafsa Mahmood by calling 708.723.3849 or via e-mail at hafsa.mahmood@sevansolutions.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005984/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
